Tango Therapeutics (TNGX) Shares Outstanding (Weighted Average) (2020 - 2026)

Tango Therapeutics' Shares Outstanding (Weighted Average) history runs 7 years deep, the most recent figure standing at $143.6 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) rose 30.17% year-over-year to $143.6 million; the TTM figure through Mar 2026 stood at $143.6 million (up 30.17% YoY), while the FY2025 annual figure was $116.2 million, up 6.35% from the prior year.
• Shares Outstanding (Weighted Average) was $143.6 million for Q1 2026 at Tango Therapeutics, up from $116.2 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $143.6 million in Q1 2026 to a low of $87.7 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $102.3 million across 5 years, with a median of $108.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) jumped 110.87% in 2022, then gained 0.5% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $87.8 million in 2022, then advanced by 7.69% to $94.6 million in 2023, then gained by 15.5% to $109.2 million in 2024, then gained by 6.35% to $116.2 million in 2025, then advanced by 23.6% to $143.6 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $143.6 million (Q1 2026), $116.2 million (Q4 2025), and $110.8 million (Q3 2025), per Business Quant data.